Stocks · Health care · Pharmaceutical Preparations

Contineum Therapeutics, Inc.

CTNM Clue Score32
United States Fiscal year ends December CIK 0001855175 Results filed 3 Nov 2026

What the insiders did Scheduled selling only

Insider
Date
Role
Action
Shares
Price
Amount
Daniel S. Lorrain
1 Jun 2026
Chief Scientific Officer
Sold on a plan
4,170
$13.16
$54.86K
Daniel S. Lorrain
1 May 2026
Chief Scientific Officer
Sold on a plan
300
$13.84
$4.15K
Daniel S. Lorrain
1 May 2026
Chief Scientific Officer
Sold on a plan
3,870
$13.06
$50.54K
Daniel S. Lorrain
6 Apr 2026
Chief Scientific Officer
Sold on a plan
4,170
$13.43
$56.01K
Daniel S. Lorrain
2 Mar 2026
Chief Scientific Officer
Sold on a plan
4,170
$15.01
$62.59K
Daniel S. Lorrain
3 Feb 2026
Chief Scientific Officer
Sold on a plan
1,170
$15.25
$17.84K
Daniel S. Lorrain
3 Feb 2026
Chief Scientific Officer
Sold on a plan
3,000
$14.82
$44.47K
Daniel S. Lorrain
5 Jan 2026
Chief Scientific Officer
Sold on a plan
500
$11.13
$5.56K
Daniel S. Lorrain
5 Jan 2026
Chief Scientific Officer
Sold on a plan
3,670
$10.35
$37.98K
Daniel S. Lorrain
23 Dec 2025
Chief Scientific Officer
Sold on a plan
4,170
$12.23
$51.01K
Daniel S. Lorrain
25 Nov 2024
Chief Scientific Officer
Sold on a plan
1,010
$16.02
$16.18K
Daniel S. Lorrain
18 Nov 2024
Chief Scientific Officer
Sold on a plan
99
$17.05
$1.69K
Daniel S. Lorrain
18 Nov 2024
Chief Scientific Officer
Sold on a plan
6,091
$16.37
$99.73K

What was left out

Form 4 filings counted 63
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 1
Sales on a Rule 10b5-1 plan 13
Sales straight out of an exercise 21
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 644,767
History held since 11 Apr 2024